Oxurion NV (FRA:TG40) Shareholder Yield % : 114.93% (As of Dec. 2025) — 71731% Above Median


What is Oxurion NV Shareholder Yield %?

Oxurion NV FRA:TG40 Shareholder Yield % is 114.93% as of Dec. 2025, which is 71731% above its 10-year median of 0.16. The stock has 7 warning signs investors should review. Among 1,297 Biotechnology companies, Oxurion NV ranks better than 99.31% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Oxurion NV's Shareholder Yield % was 114.93%.


Oxurion NV  (FRA:TG40) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Oxurion NV Shareholder Yield % Related Terms


Oxurion NV Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Oxurion NV's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxurion NV Shareholder Yield % Chart

Oxurion NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.69 -154.69 -113.99 2.81 107.61

Oxurion NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -113.99 -215.07 2.81 410.39 107.61

FRA:TG40 vs VRTX, REGN, ALNY: Shareholder Yield % Comparison

For the Biotechnology subindustry, Oxurion NV's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxurion NV Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Shareholder Yield % falls into.



Oxurion NV Shareholder Yield % Calculation

Oxurion NV's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+3873.93 %
=3873.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 114.93% mean?
Oxurion NV (FRA:TG40) has a Shareholder Yield % of 114.93% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Oxurion NV and its competitors. This is 71731% above median its historical median of 0.16. According to the industry distribution chart, Oxurion NV ranks #9 out of 1297 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Oxurion NV's Shareholder Yield % too high?
Oxurion NV's current Shareholder Yield % of 114.93% is 71731% above median its 10-year median of 0.16. Based on the distribution chart, Oxurion NV ranks #9 out of 1297 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Oxurion NV's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxurion NV ranks #9 out of 1297 companies for Shareholder Yield %. This places Oxurion NV in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Oxurion NV and its competitors. Oxurion NV's current Shareholder Yield % is 114.93%, which is 71731% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxurion NV stock overvalued right now?
Oxurion NV (FRA:TG40) has a current Shareholder Yield % of 114.93%. The current Shareholder Yield % is 114.93%, which is 71731% above median its 10-year median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Oxurion NV (FRA:TG40), the current Shareholder Yield % is 114.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxurion NV Business Description

Other Exchanges TG40:GermanyOXUR:Belgium
Address Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.